» Articles » PMID: 37241729

Chemical Constitution, Pharmacological Effects and the Underlying Mechanism of Atractylenolides: A Review

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 May 27
PMID 37241729
Authors
Affiliations
Soon will be listed here.
Abstract

Atractylenolides, comprising atractylenolide I, II, and III, represent the principal bioactive constituents of , a traditional Chinese medicine. These compounds exhibit a diverse array of pharmacological properties, including anti-inflammatory, anti-cancer, and organ-protective effects, underscoring their potential for future research and development. Recent investigations have demonstrated that the anti-cancer activity of the three atractylenolides can be attributed to their influence on the JAK2/STAT3 signaling pathway. Additionally, the TLR4/NF-κB, PI3K/Akt, and MAPK signaling pathways primarily mediate the anti-inflammatory effects of these compounds. Atractylenolides can protect multiple organs by modulating oxidative stress, attenuating the inflammatory response, activating anti-apoptotic signaling pathways, and inhibiting cell apoptosis. These protective effects extend to the heart, liver, lung, kidney, stomach, intestine, and nervous system. Consequently, atractylenolides may emerge as clinically relevant multi-organ protective agents in the future. Notably, the pharmacological activities of the three atractylenolides differ. Atractylenolide I and III demonstrate potent anti-inflammatory and organ-protective properties, whereas the effects of atractylenolide II are infrequently reported. This review systematically examines the literature on atractylenolides published in recent years, with a primary emphasis on their pharmacological properties, in order to inform future development and application efforts.

Citing Articles

Atractylenolide I ameliorates post-infectious irritable bowel syndrome by inhibiting the polymerase I and transcript release factor and c-Jun N-terminal kinase/inducible nitric oxide synthase pathway.

Jianan Y, Kunming C, Chao L, Xiang Z, Zeyu D, Bing L J Tradit Chin Med. 2025; 45(1):57-65.

PMID: 39957159 PMC: 11764933. DOI: 10.19852/j.cnki.jtcm.2025.01.006.


Atractylenolide I prevents acute liver failure in mouse by regulating M1 macrophage polarization.

Zhang H, Gao M, Wang H, Zhang J, Wang L, Dong G Sci Rep. 2025; 15(1):4015.

PMID: 39893238 PMC: 11787394. DOI: 10.1038/s41598-025-86977-x.


A Randomized, Double-Blind, Placebo-Controlled Trial Protocol Using the Fuzhengxiaoliu Patch for the Management of Primary Liver Cancer Pain.

Li S, Wang B, Deng J, Li H, Wu Y, Fang Y J Pain Res. 2025; 18:33-42.

PMID: 39802415 PMC: 11721491. DOI: 10.2147/JPR.S500305.


: An Important Model for Exploring the Pathways of Inflammatory Bowel Disease (IBD) in the Intestinal Tract.

Zeng C, Liu F, Huang Y, Liang Q, He X, Li L Int J Mol Sci. 2024; 25(23).

PMID: 39684456 PMC: 11641265. DOI: 10.3390/ijms252312742.


Atractylenolide-I Ameliorates Motor Deficits and Reduces Inflammation of the Spinal Cord by SIRT1/PGC-1α Pathway in MPTP Subacute Mouse Model of Parkinson's Disease [Letter].

Wen X, Xiao Z Neuropsychiatr Dis Treat. 2024; 20:2057-2058.

PMID: 39494381 PMC: 11531294. DOI: 10.2147/NDT.S500373.


References
1.
Zhao H, Ji Z, Liu C, Yu X . Neuroprotection and mechanisms of atractylenolide III in preventing learning and memory impairment induced by chronic high-dose homocysteine administration in rats. Neuroscience. 2015; 290:485-91. DOI: 10.1016/j.neuroscience.2015.01.060. View

2.
Novianti E, Katsuura G, Kawamura N, Asakawa A, Inui A . Atractylenolide-III suppresses lipopolysaccharide-induced inflammation via downregulation of toll-like receptor 4 in mouse microglia. Heliyon. 2021; 7(10):e08269. PMC: 8569437. DOI: 10.1016/j.heliyon.2021.e08269. View

3.
Liu J, Chen D, Bao T, Fan F, Yu C . The Anticancer Effects of Atractylenolide III Associate With the Downregulation of Jak3/Stat3-Dependent IDO Expression. Front Pharmacol. 2020; 10:1505. PMC: 6983677. DOI: 10.3389/fphar.2019.01505. View

4.
Gao H, Zhu X, Xi Y, Li Q, Shen Z, Yang Y . Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress. Exp Ther Med. 2018; 15(2):1574-1579. PMC: 5776173. DOI: 10.3892/etm.2017.5517. View

5.
Wang M, Li X, Zhang M, Ye Q, Chen Y, Chang X . Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation. Front Oncol. 2021; 11:738534. PMC: 8526898. DOI: 10.3389/fonc.2021.738534. View